Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Metastatic Melanoma
100%
Melanoma Treatment
100%
Nanoparticle Treatment
100%
Tumor
25%
Malignancy
25%
Adverse Effects
25%
Tumor Cell Proliferation
25%
Immune System
25%
Difficult-to-treat
25%
T Cell Activation
25%
Drug Resistance
25%
Signal Transduction Pathway
25%
Cancer Cell Growth
25%
Diagnostic Tool
25%
Improved Survival
25%
BRAF mutation
25%
Nanotherapeutics
25%
Chemoresistance
25%
Cancer Cell Survival
25%
Targeted Therapy
25%
Improved Prognosis
25%
Vemurafenib
25%
BRAF Inhibitor (BRAFi)
25%
Cellular Crosstalk
25%
Highly Aggressive
25%
Anti-cytotoxic
25%
Ipilimumab
25%
Cytotoxic T-lymphocyte antigen-4 (CTLA-4)
25%
Promising Treatment
25%
Multimodal Nanoparticles
25%
Medicine and Dentistry
Metastatic Melanoma
100%
Nanoparticle
100%
Drug Resistance
50%
Cancer Cell
25%
Neoplasm
25%
Cancer
25%
Cell Proliferation
25%
Tumor Cell
25%
Cell Survival
25%
T Cell
25%
Side Effect
25%
Signal Transduction Pathway
25%
Targeted Therapy
25%
Hope
25%
Vemurafenib
25%
Ipilimumab
25%
Cytotoxic T Lymphocyte Antigen 4 Antibody
25%
Cell Activity
25%
Melanoma
25%
Immune System
25%
Pharmacology, Toxicology and Pharmaceutical Science
Metastatic Melanoma
100%
Nanoparticle
100%
Neoplasm
50%
Drug Resistance
50%
Malignant Neoplasm
25%
Side Effect
25%
Melanoma
25%
Vemurafenib
25%
Cytotoxic T Lymphocyte Antigen 4 Antibody
25%
Ipilimumab
25%